Autologous T cells are gene-modified to express a high-affinity TCR specific for the MAGE-A4 peptide presented by HLA-A*02:01. Upon recognizing the peptide–HLA complex on tumor cells, the introduced TCR triggers TCR/CD3 signaling, leading to T-cell activation and cytotoxic killing of target cells. Activity is HLA-A*02:01–restricted and antigen-dependent, and therapy is administered after lymphodepletion to enhance engraftment and function.